Industry

Orphan Drug designation allows companies a 7-year marketing exclusivity period, should the treatment be approved. Click to View Article

How would you like to buy lunch with Will Kassoy, the new president of Omaze? I’m just kidding, but Kassoy has joined a company that makes such things possible. Click to View Article

YieldStreet, the alternative investment platform for retail investors, has agreed to acquire Athena Art Finance from the Carlyle Group and its co-investors for $170M. Click to View Article

Third Pole Therapeutics Announces Inhaled Nitric Oxide Strategic Collaboration with Actelion, a Janssen Pharmaceutical Company of Johnson & Johnson Click to View Article

YieldStreet, the fintech startup bringing alternative investments to the masses, has raised $62 million in financing, led by Edison Partners, the growth equity investment firm. Click to View Article

When YieldStreet launched a $6.45 million offering on its marketplace, it expected a lot of investors to get in on the deal. After all, they had about seventy-two hours to digest all the important aspects of the company and the … Continued

Knopp Biosciences LLC, a drug discovery and development company, announced the appointment of Mark Kreston as its chief commercial officer in a release. Click to View Article

Milind Mehere keeps plenty of copies of Hillbilly Elegy, J.D. Vance’s best-selling memoir about poverty in the Rust Belt, on hand for visitors to his Midtown Manhattan office. Mehere talks about how ordinary people are shut out of opportunities to … Continued

In the introductory chapter of my recently published Sports Business book, I wrote: “Because sports engender greater emotions and engagement levels than your average business, and as we consume sport differently due to technological advancements, all players within this ecosystem (sponsors, … Continued